#USA #NRx Pharmaceuticals #Wilmington #Hope Therapeutics #psychiatric treatments

NRx Pharmaceuticals and HOPE Therapeutics Join Forces for Fireside Chat

In an exciting development for the biopharmaceutical and mental health sectors, NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and its interventional psychiatry subsidiary, HOPE Therapeutics™, Inc., will participate in an engaging fireside discussion hosted by H.C. Wainwright on Tuesday, April 22, 2025. This event promises to give investors and stakeholders a closer look at the innovative psychiatric treatments being developed by these two pioneering companies.

Event Details

The fireside chat is scheduled for April 22, 2025, at 10 AM EDT. It will feature insights from Dr. Jonathan Javitt, the founder, chairman, and CEO of NRx Pharmaceuticals, alongside his role as co-CEO of HOPE Therapeutics. The discussion will be led by Vernon Bernardino, a senior biotech analyst at H.C. Wainwright, ensuring an informative session rich with expertise.

Those interested in attending can watch the event through a live webcast available at the official NRx Pharmaceuticals event page.

About NRx Pharmaceuticals

NRx Pharmaceuticals is at the forefront of biopharmaceutical innovation, focusing on developing groundbreaking therapeutics that target central nervous system disorders. Their prominent project, NRX-101, is classified as an FDA-designated Breakthrough Therapy aimed at treating suicidal treatment-resistant bipolar depression and chronic pain. The company is actively working towards filing a New Drug Application (NDA) for accelerated approval of NRX-101, which offers hope for patients struggling with debilitating mental health issues.

Additionally, NRx is seeking to expand its treatment options with NRX-100 (IV ketamine), designed to address suicidal depression. Recent clinical trials, conducted under the national auspices of the NIH, demonstrate promising results for this cutting-edge therapy, further highlighting NRx's commitment to mental health advancements.

About HOPE Therapeutics

As a wholly-owned subsidiary of NRx Pharmaceuticals, HOPE Therapeutics aims to establish a nationwide network of interventional psychiatry clinics. Their goal is to provide patients struggling with suicidal depression and related disorders with access to state-of-the-art therapies, including ketamine and transcranial magnetic stimulation (TMS). Furthermore, HOPE is developing a digital platform designed to enhance and sustain the therapeutic benefits achieved through NMDA-targeted drug therapies.

This fireside chat is not just a corporate event but an opportunity for NRx and HOPE to share their vision and strategies for combating the mental health crisis affecting countless individuals today. By leveraging innovative therapies and an integrative healthcare approach, these companies are paving the way for future advancements in psychiatric treatment.

Conclusion

As the industry turns its focus towards mental health, NRx Pharmaceuticals and HOPE Therapeutics stand at the intersection of need and innovation. Their participation in the upcoming H.C. Wainwright fireside chat represents a significant moment for stakeholders, investors, and anyone interested in the future of psychiatric care. Mark your calendars for April 22, 2025, and don't miss this chance to gain valuable insights into the advancements in mental health treatments.

For more information on NRx Pharmaceuticals and HOPE Therapeutics, visit their official websites or reach out to their respective representatives.